1
项与 CD123 CAR-T cells(Hebei Senlang Biotechnology Co. Ltd.) 相关的临床试验Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia
This is an open, single-arm, phase I clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting CD123 in the treatment of Acute Myelocytic Leukemia. A total of 15 patients are planned to be enrolled following up one year.
100 项与 CD123 CAR-T cells(Hebei Senlang Biotechnology Co. Ltd.) 相关的临床结果
100 项与 CD123 CAR-T cells(Hebei Senlang Biotechnology Co. Ltd.) 相关的转化医学
100 项与 CD123 CAR-T cells(Hebei Senlang Biotechnology Co. Ltd.) 相关的专利(医药)
100 项与 CD123 CAR-T cells(Hebei Senlang Biotechnology Co. Ltd.) 相关的药物交易